Last updated: 2026-10-13 07:56:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rani Therapeutics Holdings, Inc. (RANI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,75, with a market capitalisation of $92,22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,45 to $3,87. This page covers its latest market performance, valuation, price trends and company information.
$92,22M | |
$0,79 | |
$36,27 | |
$0,39 | |
$0,80 | |
424,59K | |
729,04K | |
-- | |
$3,87 | |
$0,45 | |
-- | |
-- |
Rani Therapeutics Holdings, Inc. (RANI) last closed at $0,80 as of 2026-10-12 23:44:00, unchanged from the previous close of $0,80.
During the latest regular trading session, RANI traded between $0,39 and $36,27, with a volume of 424,59K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Rani Therapeutics Holdings, Inc. (RANI) moved from $0,81 to $0,75, representing a decline of 7,25% ($0,06).
The stock traded between $0,75 and $0,84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 473,62 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9,0%
RANI is currently trading at $0,75, placing it 9,0% of the way from its 52-week low of $0,45 to its 52-week high of $3,87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 69 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rani Therapeutics Holdings, Inc. (RANI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.